NCT03935893
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MSI-H, MMR
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: Brain, Leptomeningeal Disease
Additional Notes: Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible – see trial for details
Exclusions: 
https://ClinicalTrials.gov/show/NCT03935893